WallStSmart

Edwards Lifesciences Corp (EW)vsMasimo Corporation (MASI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 318% more annual revenue ($6.51B vs $1.56B). EW leads profitability with a 15.4% profit margin vs 4.9%. EW appears more attractively valued with a PEG of 1.92. MASI earns a higher WallStSmart Score of 56/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48

MASI

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 8.0
Piotroski: 6/9Altman Z: 3.43
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+68.9%)

Margin of Safety

+68.9%

Fair Value

$254.99

Current Price

$84.37

$170.62 discount

UndervaluedFair: $254.99Overvalued
MASIUndervalued (+4.8%)

Margin of Safety

+4.8%

Fair Value

$141.89

Current Price

$179.95

$38.06 discount

UndervaluedFair: $141.89Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

MASI3 strengths · Avg: 9.3/10
EPS GrowthGrowth
214.4%10/10

Earnings expanding 214.4% YoY

Altman Z-ScoreHealth
3.4310/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
23.6%8/10

Strong operational efficiency at 23.6%

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
51.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

MASI4 concerns · Avg: 2.8/10
Price/BookValuation
11.9x4/10

Trading at 11.9x book value

Profit MarginProfitability
4.9%3/10

4.9% margin — thin

PEG RatioValuation
4.832/10

Expensive relative to growth rate

P/E RatioValuation
44.4x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bull Case : MASI

The strongest argument for MASI centers on EPS Growth, Altman Z-Score, Operating Margin.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.

Bear Case : MASI

The primary concerns for MASI are Price/Book, Profit Margin, PEG Ratio. A P/E of 44.4x leaves little room for execution misses. Thin 4.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

EW profiles as a mature stock while MASI is a value play — different risk/reward profiles.

MASI carries more volatility with a beta of 1.10 — expect wider price swings.

EW is growing revenue faster at 13.6% — sustainability is the question.

EW generates stronger free cash flow (585M), providing more financial flexibility.

Bottom Line

MASI scores higher overall (56/100 vs 55/100). EW offers better value entry with a 68.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Masimo Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Masimo Corporation develops, manufactures and markets non-invasive monitoring technologies and hospital automation solutions globally. The company is headquartered in Irvine, California.

Visit Website →

Want to dig deeper into these stocks?